<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article57</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/LEADER" style="display:block; margin-bottom:10px;">LEADER Original</a></li>
<h2><strong>LEADER</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes".The New England Journal of Medicine. 2016. <br/>
<br/>
<h2><strong>Contents:</strong></h2><br/>
<br/>
1. Clinical Question<br/>
<br/>
2. Bottom Line<br/>
<br/>
3. Major Points<br/>
<br/>
4. Guidelines<br/>
<br/>
5. Design<br/>
<br/>
6. Population<br/>
<br/>
6.1 Inclusion Criteria<br/>
<br/>
6.2 Exclusion Criteria<br/>
<br/>
6.3 Baseline Characteristics<br/>
<br/>
7. Interventions<br/>
<br/>
8. Outcomes<br/>
<br/>
8.1 Primary Outcomes<br/>
<br/>
8.2 Secondary Outcomes<br/>
<br/>
9. Funding<br/>
<br/>
10. Further Reading<br/>
<br/>
<h2><strong>Clinical Question:</strong></h2><br/>
<br/>
Does the addition of liraglutide to standard care improve cardiovascular outcomes in patients with type 2 diabetes and high cardiovascular risk?<br/>
<br/>
<h2><strong>Bottom Line:</strong></h2><br/>
<br/>
Among patients with type 2 diabetes and high cardiovascular risk, liraglutide added to standard care reduced the risk of major cardiovascular events and death from any cause.<br/>
<br/>
<h2><strong>Major Points:</strong></h2><br/>
<br/><br/>
<br/>
<h2><strong>Guidelines:</strong></h2><br/>
<br/>
As of this trial's publication, no guidelines have been updated to reflect the results of this study.<br/>
<br/>
<h2><strong>Design:</strong></h2><br/>
<br/>
Multicenter, double-blind, placebo-controlled, randomized controlled trial. <br/>
<br/>
<h2><strong>Population:</strong></h2><br/>
<br/>
N=9,340 patients with type 2 diabetes and high cardiovascular risk.<br/>
<br/>
<h2><strong>Interventions:</strong></h2><br/>
<br/>
Patients were randomized to receive either 1.8 mg (or the maximum tolerated dose) of liraglutide or a placebo once daily as a subcutaneous injection in addition to standard care.<br/>
<br/>
<h2><strong>Outcomes:</strong></h2><br/>
<br/>
Primary Outcomes:<br/>
- The composite of first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke occurred significantly less in the liraglutide group compared with the placebo group.<br/>
- Death from cardiovascular causes and death from any cause were also lower in the liraglutide group.<br/>
<br/>
Secondary Outcomes:<br/>
- Nonsignificant reductions were seen with liraglutide compared to placebo for nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure.<br/>
- Fewer microvascular events were observed in the liraglutide group.<br/>
- Adverse events leading to discontinuation of liraglutide were mainly gastrointestinal.<br/>
<br/>
<h2><strong>Funding:</strong></h2><br/>
<br/>
Funded by Novo Nordisk and grants from the National Institutes of Health.<br/>
<br/>
<h2><strong>Further Reading:</strong></h2><br/>
<br/>
For full details of the study, readers should refer to the original publication and supplementary materials provided by the New England Journal of Medicine.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
